The steering committee for the DKMS defined eleven organizational and clinical quality indicators and standards to monitor the Danish breast cancer screening program.
12 The eleven organizational and clinical quality indicators and standards defined by the DKMS steering committee to monitor the Danish breast cancer screening program are participation, screening interval, time to result, radiation dose, recall, interval cancers, invasive tumors, node negative cancers, small cancers, breast conserving therapy, and ratio of surgery for benign to malignant lesions.
Women were enrolled and monitored in the breast health centre of a tertiary care centre (Women and Infants Hospital, Providence, Rhode Island, USA).
The decision is impacted by concerns about developing another cancer, the need for another surgery in the future, aesthetic results obtained after breast reconstruction that currently disappoint many patients and financial costs connected to monitoring the healthy breast and/or future second intervention.
Breast Screening Quality Assurance Reference Centres have a responsibility to monitor the performance of breast screening services and to feed relevant outcome data back to them.
Preliminary clinical research is now under way to look at how the technology can be used to monitor the development of breast cancer and identify how far it has progressed.Even with mammography and ultrasound, the current gold standards for breast-cancer screening, doctors cannot tell if a tumour is malignant or benign without performing an invasive and expensive biopsy.
The need to monitor the survivability of breast cancer patients is threefold.
We have conducted a preliminary investigation using MT to monitor the progression of breast cancer response to neoadjuvant chemotherapy.
F-FDG-PET has also been evaluated as a tool with which to monitor the response of breast cancer bone metastases to therapy.
Collectively, the data suggest that the zebrafish embryo model can be used to monitor the migration of breast cancer cells in a living animal, and let-7a overexpression or CCR7 silencing could cause a significant reduction in breast cancer cell migration in vivo.
